Avantor says it is expanding its Bridgewater, NJ innovation center in a move that nearly doubles the laboratory and support space.
“Innovation is about solving customer problems in a rapidly progressing biotechnology environment using contemporary technologies and thinking,” stated Ger Brophy, PhD, executive vice president, biopharma production at Avantor. “We collaborate with our customers from their initial discovery and development activities through scale-up and commercialization. Our solutions support industry downward cost pressure by emphasizing supply chain efficiency and improving production process performance.”
Avantor’s expanded innovation center will increase the company’s research and development support for customized product and bioprocess development, and custom cell and gene therapy reagent manufacturing to support customers’ therapeutic products that are developed for advancements in personalized medicine, adds Brophy.
He also notes that the site capabilities strengthen new bioprocessing products designed to help minimize risk of contamination and variability for cell and gene therapy, mAbs, and vaccines, including high purity products, single-use solutions, and small volume cGMP reagents in single use bags.
The site developed Avantor’s recently launched novel J.T.Baker® BAKERBOND® PROchievA™ recombinant protein A resin for purifying monoclonal antibodies (mAbs) and other complex molecules.
The innovation center expansion follows the December 2019 opening of Avantor’s innovation and customer support center in Shanghai, China.
